Integrating ferroptosis and the tumor-immune gene mutations interface: a novel lenvatinib resistance prognostic signature with YWHAB-related immunotherapeutic correlates in hepatocellular carcinoma.
Targeting YWHAB may represent a promising therapeutic strategy to overcome lenvatinib resistance in HCC, and the FLRPS serves as an effective predictive model for the prognosis of HCC.